- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04511455
Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
A Phase II, Non-randomized, Single Arm, Translational Study of Cabozantinib for Patients With Hepatocellular Carcinoma (HCC) Refractory to First Line Treatment
Study Overview
Status
Intervention / Treatment
Detailed Description
This is a open-label, single-arm, multicenter phase II trial for patients with locally advanced and/or metastatic and/or unresectable hepatocellular carcinoma (HCC).
Patients who have histologically proven or were clinically diagnosed (by guideline criteria in cirrhotic patients) with locally advanced or metastatic and/or unresectable HCC will be included to receive cabozantinib peroral 60 mg/day. A stepwise dose de-escalation schedule on individual level is available for patients with lower tolerability against cabozantinib.
The study treatment will be limited to a maximum of 12 months (including temporary interruptions).
Tumor tissue will be collected for accompanying research project. (Participation is optional for participant).
During treatment, clinical visits (blood cell counts, ECG, detection of toxicity) occur every four weeks during treatment phase. Safety will be monitored continuously by careful monitoring of all adverse events (AEs) and serious adverse events (SAEs) reported.
During treatment, tumor response will be assessed by the Investigator according to RECIST 1.1 (radiological imaging by CT and/or MRI of the chest, abdomen, pelvis and all other sites of disease every 10 weeks until end of treatment (EOT) and every 12 weeks during follow-up (FU), in case of EOT due to other reasons than progressive disease. Safety-FU visit and Survival FU visits will be assessed 30 days-, and every 12 weeks after EOT.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Arndt Vogel, Prof. Dr.
- Phone Number: +49 511 532 9590
- Email: vogel.arndt@mh-hannover.de
Study Contact Backup
- Name: Johanna Riedel, Dr.
- Phone Number: +49 69 7601 4635
- Email: riedel.johanna@ikf-khnw.de
Study Locations
-
-
-
Bad Saarow, Germany, 15526
- Recruiting
- HELIOS Klinikum Bad Saarow
-
Contact:
- Daniel Pink, Dr.
-
Halle, Germany, 06120
- Recruiting
- Universitätsklinikum Halle (Saale)
-
Contact:
- Marko Damm, Dr.
-
Hannover, Germany, 30625
- Recruiting
- Medizinische Hochschule Hannover
-
Contact:
- Arndt Vogel, Prof. Dr.
-
Kiel, Germany, 24105
- Recruiting
- Universitätsklinikum Schleswig-Holstein
-
Contact:
- Rainer Günther, Dr.
-
Köln, Germany, 50937
- Recruiting
- Universitätsklinikum Köln
-
Contact:
- Dirk Waldschidt, Dr.
-
Landshut, Germany, 84036
- Recruiting
- VK&K Studien
-
Contact:
- Florian Kaiser, Dr.
-
Lübeck, Germany, 23538
- Recruiting
- Universitätsklinikum Schleswig-Holstein
-
Contact:
- Jens Marquardt, Prof.
-
München, Germany, 81675
- Recruiting
- Klinikum Rechts Der Isar Der Technischen Universität München
-
Contact:
- Ursula Ehmer, PD Dr.
-
Neuss, Germany, 41462
- Recruiting
- Johanna Etienne Krankenhaus
-
Contact:
- Wolf Köster, Dr.
-
Ulm, Germany, 89081
- Recruiting
- Universitatsklinikum Ulm
-
Contact:
- Thomas Ettrich, Dr.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Fully-informed written consent.
Males and females ≥ 18 years of age.
*There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.
- Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology/ cytology or clinically by guideline criteria in cirrhotic patients
- Disease that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies.
- Patients who have shown progressive disease during or after first line therapy OR patients must have had their treatment interrupted due to the level of toxicities AND cabozantinib therapy is intended as second line therapy.
- ECOG performance status ≤ 2.
- Resolution of any acute, clinically significant treatment-related toxicity from prior therapy to Grade 1 prior to study entry, with the exception of alopecia.
- For women of childbearing potential and men who are sexually active with women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods.
Exclusion Criteria:
- Unwillingness to give informed consent for participation in the study.
- Prior sorafenib treatment.
- Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment or within at least 5 months after last dose of study treatment.
- Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.
- Significant portal hypertension (moderate or severe ascites).
- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.
- Liver cirrhosis Child-Pugh B with > 7 points and Child-Pugh C.
- Severely impaired kidney function.
- History of encephalopathy in past 12 months, if not completely regressive or more than one episode within the last 6 months.
- Significant cardiovascular disease (such as New York Heart Association Class II or greater cardiac disease, myocardial infarction, or cerebrovascular accident) within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina.
- Baseline QTcF >500 ms.
- Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study.
- Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia.
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications.
- Elevations of AST/ALT exceeding 5 X ULN.
- Treatment with investigational systemic therapy within 28 days prior to initiation of study treatment.
- Prior cabozantinib use.
- Is currently participating or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.
- Patients who have been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
- Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental
Cabozantinib peroral 60 mg/day A stepwise dose de-escalation schedule on individual level is available for patients with lower tolerability against cabozantinib. The study treatment will be limited to a maximum of 12 months (including interruptions). |
Cabozantinib 60 mg/day peroral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time-on-treatment
Time Frame: at study end (approx. 30 months after FPI)
|
Time on treatment will be assessed as time from date of first dose of cabozantinib intake till date of permanent discontinuation of treatment.
|
at study end (approx. 30 months after FPI)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: at 18 months after last patient randomized
|
Survival rates will be assessed from the date of first dose of cabozantinib intake to the date of death from any cause using Kaplan-Meier methods.
|
at 18 months after last patient randomized
|
Progression free survival (PFS)
Time Frame: at study end (approx. 18 months after last patient randomized)
|
Survival rates for the different time points will be determined using the Kaplan-Meier analysis and RECIST 1.1.
|
at study end (approx. 18 months after last patient randomized)
|
Objective response rate (ORR)
Time Frame: at study end (approx. 18 months after last patient randomized)
|
Objective response rate will be defined as the proportion of subjects experiencing a confirmed complete response (CR) or confirmed partial response (PR) per RECIST 1.1.
|
at study end (approx. 18 months after last patient randomized)
|
Duration of response
Time Frame: at study end (approx. 18 months after last patient randomized)
|
Time from documentation of tumor response to disease progression.
|
at study end (approx. 18 months after last patient randomized)
|
Treatment exposure
Time Frame: at study end (approx. 18 months after last patient randomized)
|
Time on treatment/dose intensity/dose reductions
|
at study end (approx. 18 months after last patient randomized)
|
Toxicity: o Treatment-related adverse events (TRAEs) o TRAE related treatment interruptions o TRAE related treatment modifications o TRAE related treatment discontinuations
Time Frame: at study end (approx. 18 months after last patient randomized)
|
All observed toxicities and side effects will be graded according to NCI CTCAE v5.0 and the degree of association of each with the study treatment assessed and summarized.
|
at study end (approx. 18 months after last patient randomized)
|
Change in ECOG Performance Status
Time Frame: at study end (approx. 18 months after last patient randomized)
|
Eastern Cooperative Oncology Group patient performance status (Grading from 0 to 5)
|
at study end (approx. 18 months after last patient randomized)
|
Change in ALBI Grade
Time Frame: at study end (approx. 18 months after last patient randomized)
|
ALBI score = -0.085
× (albumin g/L) + 0.66 × l g(TBil μmol/L)
|
at study end (approx. 18 months after last patient randomized)
|
Change in Child Pugh Score
Time Frame: at study end (approx. 18 months after last patient randomized)
|
Child-Pugh Classification Score (Grading from A to C)
|
at study end (approx. 18 months after last patient randomized)
|
Translational research
Time Frame: at study end (approx. 18 months after last patient randomized)
|
Correlation of biomarkers potentially associated with clinical efficacy (OS, PFS and ORR) of cabozantinib by NGS Oncopanel analysis and VEGF module expression analysis.
|
at study end (approx. 18 months after last patient randomized)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Arndt Vogel, Prof. Dr., Hannover Medical School
- Study Director: Salah-Eddin Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AURORA (Other Identifier: Mayo Clinic)
- 2019-004728-39 (EudraCT Number)
- AIO-HEP-0419/ass (Other Identifier: AIO-Studien-gGmbH)
- IKF-t018 (Other Identifier: IKF Trial ID)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Carcinoma Non-resectable
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
Tianjin Medical University Cancer Institute and...RecruitingHepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectableChina
-
Chang Gung Memorial HospitalRecruitingHepatocellular Carcinoma Non-resectableTaiwan
-
Second Affiliated Hospital of Guangzhou Medical...First People's Hospital of Foshan; Affiliated Cancer Hospital & Institute of... and other collaboratorsRecruitingHepatocellular Carcinoma Non-resectableChina
-
Terumo Europe N.V.RecruitingHepatocellular Carcinoma Non-resectableBelgium, Germany, Italy
-
Second Affiliated Hospital of Guangzhou Medical...RecruitingHepatocellular Carcinoma Non-resectableChina
-
UMC UtrechtErasmus Medical Center; Dutch Cancer Society; Quirem Medical B.V.CompletedHepatocellular Carcinoma | Hepatocellular Carcinoma Non-resectableNetherlands
-
Second Affiliated Hospital of Guangzhou Medical...Active, not recruitingHepatocellular Carcinoma Non-resectableChina
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer Network; AVEO...CompletedAdvanced Adult Hepatocellular Carcinoma | Non-Resectable Hepatocellular CarcinomaUnited States
-
Tongji HospitalGeneplus-Beijing Co. Ltd.RecruitingHepatocellular Carcinoma Non-resectableChina
Clinical Trials on Cabozantinib
-
University of BolognaIpsen; Bioikos Ambiente Srl; AOU S.Orsola Malpighi-Unit of Oncologic Molecular... and other collaboratorsUnknownNon Small Cell Lung CancerItaly
-
ExelixisCompletedCancer | NSCLC | Solid TumorsJapan
-
University of WashingtonNational Cancer Institute (NCI); Prostate Cancer FoundationTerminatedRecurrent Prostate Cancer | Castration-resistant Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate CancerUnited States
-
Karsten GavenisRecruitingNeuroendocrine Tumors | Neuroendocrine CarcinomaGermany, Austria
-
Istituto Oncologico Veneto IRCCSActive, not recruiting
-
Spanish Oncology Genito-Urinary GroupApices Soluciones S.L.CompletedOld Age; Debility | Renal Carcinoma MetastaticSpain
-
Stephen Chan LamActive, not recruiting
-
ExelixisApproved for marketing
-
Jennifer KingExelixisRecruitingOvarian Germ Cell Tumor | Seminoma | Germ Cell Tumor | Non-seminomatous Germ Cell TumorUnited States
-
Memorial Sloan Kettering Cancer CenterExelixisRecruiting